

**Freedom of Information Request**

**Ref: 21-062**

22 February 2021

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we hold some the information you are requesting

**1. How many patients are currently (in the past 3 months Oct - Dec 20) undergoing treatment for melanoma, and how many of these are BRAF+?**

Unable to determine

**2. In the past 3 months, how many melanoma patients (any stage) were treated with the following:**

- Cobimetinib - 0
- Dabrafenib - 1
- Dabrafenib AND Trametinib - 21
- Encorafenib AND Binimetinib - 3
- Ipilimumab - 1
- Ipilimumab AND Nivolumab - 4
- Nivolumab - 33
- Pembrolizumab - 19
- Trametinib - 0
- Vemurafenib - 1
- Vemurafenib AND Cobimetinib - 0
- Other active systemic anti-cancer therapy - 0
- Palliative care only – Previously advised on similar FOIs we are unable to supply this data due to the vast number of ways patient can be referred to palliative care services some of which bypass UHB entirely.

**3. If possible, could you please provide the patients treated in the past 3 months with the following therapies for metastatic melanoma ONLY: (Caveat – patients designated as M1 in TNM staging, does not include any patients marked as unknown who may well be metastatic)**

- Ipilimumab - 1

- Ipilimumab AND Nivolumab - 4
- Nivolumab - 21
- Pembrolizumab - 9
- Any other therapies - 12

**4. In the past 3 months how many patients were treated with the following for breast cancer ?**

- Abemaciclib + Anastrozole/Exemestane/Letrozole - 6
- Abemaciclib + Fulvestrant - 18
- Alpelisib + Fulvestrant - 0
- Atezolizumab - 4
- Bevacizumab - 0
- Eribulin - 17
- Everolimus + Exemestane - 4
- Fulvestrant as a single agent - 2
- Gemcitabine + Paclitaxel - 0
- Lapatinib - 0
- Neratinib - 8
- Olaparib - 0
- Palbociclib + Anastrozole/Exemestane/Letrozole - 64
- Palbociclib + Fulvestrant - 14
- Pertuzumab + Trastuzumab + Docetaxel - 30
- Ribociclib + Anastrozole/Exemestane/Letrozole - 1
- Ribociclib + Fulvestrant - 0
- Talazoparib - 0
- Trastuzumab + Paclitaxel - 7
- Trastuzumab as a single agent - 44
- Trastuzumab emtansine - 19
- Any other active systemic anti-cancer therapy - 217

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Director of Corporate Governance  
 University Hospitals Bristol and Weston NHS Foundation Trust  
 Trust Headquarters  
 Marlborough Street  
 Bristol  
 BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

### Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

**Freedom of Information Team**  
**University Hospitals Bristol and Weston NHS Foundation Trust**